LuPSMA offers a new option for men with castration-resistant PSMA-positive metastatic cancer.
Detection may be more accurately than mpMRI
Men with low-risk prostate cancer on active surveillance report fewer problems with sexual function than those on other treatments.
Molecular imaging tools have the potential to transform how we diagnose and treat men with prostate cancer.
Study will likely change the standard of care
A discussion on the challenges associated with the use of MRI to diagnose prostate cancer including insurance coverage and patient discomfort